Skip to main content

Table 1 Treatment-by-subpopulation interactions across all three trials: endpoints at week 24 (unless otherwise stated)

From: Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies

 ACR20ACR50ACR70Change in DAS28-CRPChange in DAS28-ESRChange in CDAICDAI ≤ 2.8CDAI ≥ 58%HAQ-DI ≥ 0.22Change in HAQ-DI*mTSS**
Age
 MTX-IR combination study0.46730.64190.85160.79740.76380.97840.48890.92320.58470.5570
 TNF-IR/INT combination study0.40950.79020.28860.46950.69150.13370.58130.81730.4101
 Monotherapy study0.98610.62490.84400.97120.88190.50790.55010.68720.39830.7994
Sex
 MTX-IR combination study0.79340.78030.0643NC0.38020.43150.35000.61650.46330.5890
 TNF-IR/INT combination study0.68180.26100.20860.41340.51320.06140.79930.29990.0417
 Monotherapy study0.77330.25870.09440.63940.19530.63250.66090.68180.80290.1981
Race
 MTX-IR combination study0.47690.48270.31250.77980.56660.54790.38200.74860.28930.6911
 TNF-IR/INT combination study0.03370.01540.05290.35390.37400.00350.40850.10120.6925
 Monotherapy study0.24970.59230.94500.63760.62420.89330.99850.37300.11000.6447
Region
 MTX-IR combination study0.57150.78350.74060.20410.12340.39240.46280.81820.39000.4490
 TNF-IR/INT combination study0.73190.55720.30570.96030.97030.43810.58300.51060.9414
 Monotherapy study0.19650.26360.54680.95060.62130.82800.98650.71480.12230.1202
Weight
 MTX-IR combination study0.52610.60260.2398NCNC0.74710.92250.4171NC0.3874
 TNF-IR/INT combination study0.21720.93920.05930.22560.79180.14230.53590.27590.2538
 Monotherapy study0.23760.48710.11610.32970.25330.19910.99810.54080.09390.2366
BMI
 MTX-IR combination study0.05390.76360.46070.01660.11160.86690.54270.36840.60910.1167
 TNF-IR/INT combination study0.32190.57050.40190.16990.50890.44250.05930.88160.4860
 Monotherapy study0.00480.01860.01170.02310.04660.02390.06080.0492<0.00010.0023
Smoking history
 MTX-IR combination study0.88110.77000.5258NC0.90720.48060.57320.42580.14650.2046
 TNF-IR/INT combination study0.45880.92140.36330.29000.25820.39580.18180.61470.7203
 Monotherapy study0.25450.40510.30610.69740.38290.49940.60530.77330.13210.4093
Duration RA (</≥ 2 years)
 MTX-IR combination study0.52110.40030.11080.30180.06110.32170.15500.37960.3297NC
 TNF-IR/INT combination study0.78800.83920.07780.74890.83700.20690.92110.97950.8628
 Monotherapy study0.63000.84840.67290.28160.42050.59170.56040.95270.70080.0512
Duration RA (</≥ median)
 MTX-IR combination study0.83640.51160.16970.72860.79940.19610.15780.99310.56780.3215
 TNF-IR/INT combination study0.05160.19920.16780.31540.22610.24820.09510.22630.1228
 Monotherapy study0.29950.88560.81740.29160.82270.68430.44390.82760.20540.3787
RF
 MTX-IR combination study0.10830.38540.05640.05510.64290.18690.07660.07210.04270.8194
 TNF-IR/INT combination study0.00120.04800.30070.08870.05280.21750.00700.09960.0202
 Monotherapy study0.04160.69370.79530.21390.64100.14760.47150.47680.74970.7273
ACPA
 MTX-IR combination study0.00100.08970.16540.00120.00240.40170.05660.04900.00280.9994
 TNF-IR/INT combination study0.04530.25110.83910.08660.03790.97700.00710.51140.0929
 Monotherapy study0.00280.94420.17780.14620.47710.42490.59840.58780.03160.0337
Baseline CRP
 MTX-IR combination study0.90680.59790.60650.05370.25890.41990.39740.34550.24970.0221
 TNF-IR/INT combination study0.09480.38450.69990.80080.89000.43860.17740.01590.6836
 Monotherapy study0.03140.07590.01010.00740.00550.01520.50150.13280.05700.0006
Baseline ESR
 Monotherapy study0.50730.84520.93180.70100.12950.50700.01230.92780.25520.6488
Baseline SDAI
 MTX-IR combination study0.59630.52690.48160.14520.03990.90090.75520.60020.58040.7226
 TNF-IR/INT combination study0.59860.93990.5674NCNC0.43330.19700.2160NC
Prior bDMARD
 MTX-IR combination study0.85830.51750.19730.93450.87930.24210.22020.88580.68120.2246
Prior anti-TNFs
 TNF-IR/INT combination study0.12150.23400.09250.20520.22100.19160.27970.28530.3850
Prior csDMARDs
 MTX-IR combination study0.42080.48860.69090.39460.11830.89050.28460.90640.91110.3586
 TNF-IR/INT combination study0.49410.64410.37440.34310.11080.61550.82270.28810.7416
 Monotherapy study0.79350.23700.69670.86940.37400.55140.56020.54590.37670.9655
Background csDMARDs
 TNF-IR/INT combination study0.31940.69460.36460.16580.55730.27180.33910.55950.8590
MTX history
 Monotherapy study0.55400.39820.33130.21630.21630.25830.66310.14980.36920.6913
Glucocorticoid use
 MTX-IR combination study0.50720.63900.85550.33660.37840.71970.88910.17510.70580.9422
 TNF-IR/INT combination study0.27510.94000.83340.61420.60610.06560.56400.09940.8873
 Monotherapy study0.09070.16500.94220.06630.04140.01950.43520.00250.09620.7536
  1. ACPA anti-cyclic citrullinated peptide antibody, ACR20/50/70 American College of Rheumatology 20%/50%/70% response, bDMARD biological and targeted disease-modifying antirheumatic drug, BMI body mass index, CDAI Clinical Disease Activity Index, CRP C-reactive protein, csDMARD conventional synthetic disease-modifying antirheumatic drug, DAS28-CRP Disease Activity Score in 28 joints using CRP, DAS28-ESR Disease Activity Score in 28 joints using erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, INT intolerant, IR inadequate response, NC not calculated, mTSS Modified Total Sharp Score, MTX methotrexate, RA rheumatoid arthritis, RF rheumatoid factor, SDAI Simplified Disease Activity Index, TNF tumour necrosis factor
  2. *Assessed at week 16/12/24 in the MTX-IR combination study, TNF-IR/INT combination study, and monotherapy studies, respectively
  3. **Assessed at week 52